Keros Therapeutics (NASDAQ:KROS) Announces Earnings Results, Misses Estimates By $0.11 EPS

Keros Therapeutics (NASDAQ:KROS) posted its quarterly earnings data on Monday. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11), FiscalAI reports. Keros Therapeutics had a negative return on equity of 19.30% and a negative net margin of 256.60%.

Keros Therapeutics Trading Down 2.5%

Keros Therapeutics stock traded down $0.26 during mid-day trading on Wednesday, reaching $9.99. The company had a trading volume of 139,950 shares, compared to its average volume of 345,847. The business has a fifty day simple moving average of $10.66 and a 200 day simple moving average of $12.52. The company has a market cap of $197.70 million, a P/E ratio of -3.32 and a beta of 0.99. Keros Therapeutics has a fifty-two week low of $9.69 and a fifty-two week high of $22.55.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, Director Nima Farzan sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the transaction, the director directly owned 9,767 shares in the company, valued at approximately $104,799.91. This trade represents a 21.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the sale, the director directly owned 9,767 shares in the company, valued at $104,702.24. The trade was a 21.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,425 shares of company stock worth $89,994. Corporate insiders own 12.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its position in Keros Therapeutics by 149.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after acquiring an additional 1,888 shares during the period. New York State Common Retirement Fund lifted its holdings in shares of Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after purchasing an additional 7,700 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Keros Therapeutics by 8.6% in the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after purchasing an additional 988 shares during the last quarter. Sherbrooke Park Advisers LLC bought a new stake in shares of Keros Therapeutics in the third quarter worth $176,000. Finally, XTX Topco Ltd acquired a new stake in Keros Therapeutics in the fourth quarter valued at $212,000. 71.56% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on KROS. Zacks Research cut shares of Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 29th. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Leerink Partners lowered their price objective on shares of Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research report on Tuesday. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Keros Therapeutics in a report on Tuesday. Four research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $20.50.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.